Clinical trials: Poliovirus Vaccine, Oral
Polio
Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3
Globally, polio cases have decreased by over 99% since 1988. However, wild poliovirus cases continue in Pakistan. Conflict and lack of access to children due to on-going insecurity in tribal areas present special challenges in…
- Trial name
- SIAD (NCT01586572)
- Testing
- mOPV1, bOPV 1,3
- Where
- 2 sites in Pakistan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Poliomyelitis
A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age
The purpose of this study is to assess the safety (serious adverse events [SAEs]), and severe adverse events [AEs] (grade 3 according to CTCAE 4.03) after one dose of SABIN tOPV in 1-5 year-old children and three doses of SABIN…
- Trial name
- T2-ABMG (NCT02580201)
- Testing
- Oral Polio Vaccine
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Poliomyelitis
Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine
Type 2 component of oral poliovirus vaccine is slated for global withdrawal through a switch from trivalent oral poliovirus vaccine (tOPV) to bivalent oral poliovirus vaccine (bOPV) for preventing paralytic polio caused by…
- Trial name
- TTbOPV (NCT02785705)
- Testing
- poliovirus vaccine
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
Seroimmunity, Diarrhea
Diarrhea and Bivalent Oral Polio Vaccine Immunity
Global eradication of poliomyelitis has proven to be elusive. Although 99% of cases have been eliminated since 1988, outbreaks continue to occur, and new tools are needed to accelerate eradication.
- Conditions
- Seroimmunity, Diarrhea, Polio
- Trial name
- NCT01559636
- Testing
- bivalent oral polio vaccine
- Where
- Nepal
- Volunteers
- 699 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Poliomyelitis
Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines
The main objectives of this study are to : evaluate the safety and tolerability of trivalent novel oral poliovirus vaccines (tnOPV) in healthy adults, young children, and neonates, relative to those receiving control vaccines…
- Trial name
- NCT06137664
- Testing
- Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2), Novel oral poliomyelitis vaccine type 3 (nOPV3)
- Where
- 2 sites in Bangladesh
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- PATH
Poliomyelitis
A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants
The purpose of this phrase III clinical trial is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in a '1+2' sequential schedule with bivalent oral poliovirus vaccine in 2-month-old…
- Trial name
- NCT03822754
- Testing
- sIPV-bOPV-bOPV vaccination schedule, wIPV-bOPV-bOPV vaccination schedule
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Polio, Poliomyelitis
Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine
The purpose of this study is to generate data to support the registration extension of IMOVAX Polio to be used in a sequential vaccination.
- Trial name
- NCT01475539
- Testing
- Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio, Live oral poliovirus type 1, 2 and 3
- Where
- China
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study
This is an open-label phase IV randomized clinical trial that will assess intestinal and humoral immunity among infants who receive a combination of monovalent oral poliovirus vaccine type 1 and fractional dose of inactivated…
- Trial name
- mOPV1 (NCT03722004)
- Testing
- mOPV1, bOPV, fIPV
- Where
- Bangladesh
- Volunteers
- 1,256 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Poliomyelitis
A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania
A Phase 4 study to evaluate the safety and immunogenicity of monovalent oral polio vaccine type 2 in healthy IPV-vaccinated children aged 1 to 5 years in Lithuania.
- Trial name
- M3-ABMG (NCT02582255)
- Testing
- Sabin mOPV2
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Poliomyelitis
A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants
The purpose of this phrase III clinical trial is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in a '2+1'sequential schedule with bivalent oral poliovirus vaccine in 2-month-old…
- Trial name
- NCT03822767
- Testing
- sIPV-sIPV-bOPV vaccination schedule, wIPV-wIPV-bOPV vaccination schedule
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Covid19, SARS (Severe Acute Respiratory Syndrome)
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
- Trial name
- OPV-NA831 (NCT04540185)
- Testing
- Biological: oral polio vaccine, NA-831, Combination of oral polio vaccine and NA-831
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Poliomyelitis
Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine
The study will assess and compare the immune response and safety following the co-administration of Novel Oral Polio Type 2 (nOPV2) and bivalent Oral Polio Vaccine (bOPV) in comparison with nOPV2 or bOPV in infants aged 2 months…
- Trial name
- NCT05166031
- Testing
- bOPV and nOPV2
- Volunteers
- healthy volunteers welcome
- Sponsor
- Fidec Corporation
Rotavirus
Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants
The purpose of this study is to evaluate the immunogenicity and safety of the diphtheria, tetanus, pertussis and inactivated poliovirus (DPT-IPV) vaccine Squarekids administered with or without the GSK Biologicals' liquid Rotarix…
- Trial name
- NCT02907216
- Testing
- Squarekids, Rotarix
- Where
- 11 sites in Japan
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Polio
Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV
The goal of this clinical trial is to explore two strategies to enhance nOPV2 immunogenicity in the field and overcome potential interference of bOPV: 1.
- Trial name
- NCT06114810
- Testing
- polio vaccines: nOPV2, bOPV, IPV
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Polio
Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh
Hypothesis: The immunogenicity of oral polio vaccine (OPV) will be enhanced in Bangladeshi infants who receive bicarbonate buffer at the time of polio immunization.
- Trial name
- NCT01579825
- Testing
- Buffer
- Where
- Bangladesh
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Poliomyelitis
Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine
This is an open-label phase IV, randomized controlled trial of mOPV2 alone and mOPV2 along with IPV. This trial will assess the impact on type 2 immunogenicity by reducing the interval between mOPV2 doses.
- Trial name
- NCT02643368
- Testing
- mOPV2 at 6 and 7 weeks of age, mOPV2 at 6 and 8 weeks of age, mOPV2 at 6 and 10 weeks of age
- Where
- Bangladesh
- Volunteers
- 760 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Poliomyelitis
Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
The purpose of this clinical trial is to assess the safety and tolerability (primary objective), immunogenicity (primary and secondary objectives), fecal shedding of vaccine viruses (secondary objective) and the potential for…
- Trial name
- NCT05644184
- Testing
- Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1), Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)
- Where
- Bangladesh
- Volunteers
- 2,232 people, healthy volunteers welcome
- Sponsor
- PATH
Enterovirus Infection, Type 1 Diabetes
Live Enterovirus Vaccine and Type 1 Diabetes
Enterovirus infections may either increase or decrease the risk of type 1 diabetes depending on the age of infection and the type of enterovirus in question.
- Conditions
- Enterovirus Infection, Type 1 Diabetes, Prediabetic State
- Trial name
- NCT02961595
- Testing
- Oral Polio Vaccine (OPV)
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Tampere University
Poliomyelitis
A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine
This will be a single center, age de-escalation, partly-blinded, randomized study. The trial will be performed with the participation of 100 healthy children age 1-5 years who have been vaccinated with inactivated polio vaccine…
- Trial name
- NCT03554798
- Testing
- nOPV2 (monovalent oral polio vaccine)
- Where
- 2 sites in Panama
- Volunteers
- 1,025 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Immunity to Oral Rotavirus Vaccine, Immunity to Oral Polio Vaccine
Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines
Background: Strategies are needed to improve oral rotavirus vaccine (RV), which provides suboptimal protection in developing countries.
- Conditions
- Immunity to Oral Rotavirus Vaccine, Immunity to Oral Polio Vaccine, Shedding of Oral Rotavirus Vaccine
- Trial name
- NCT01616693
- Testing
- Probiotic, Zinc, Rotavirus vaccine
- Where
- India
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- PATH